검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 21일
현재 선택: 5개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1) Roche / Genentech·HER2 ORR 69.3%·t½ 4 h | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki) Daiichi Sankyo / AstraZeneca·HER2 ORR 71.7% | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 ORR 79.7%·t½ ~5.8 days (ADC) | ||
|---|---|---|---|---|---|
Overview Program | Kadcyla (ado-trastuzumab emtansine / T-DM1) | Fam-Trastuzumab Deruxtecan-Nxki | Enhertu (trastuzumab deruxtecan) | Disitamab Vedotin (RC48) | ZW49 |
Overview Company | Roche / Genentech | Daiichi Sankyo / AstraZeneca | Daiichi Sankyo / AstraZeneca | RemeGen | Zymeworks BC Inc. |
Overview Modality | ADC | ADC | ADC | ADC | ANTIBODY |
Overview Target | HER2 | HER2 | HER2 | HER2 | HER2 |
Overview Indication | HER2+ breast cancer | HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer | HER2+ breast cancer, HER2-low, gastric | HER2+ urothelial, gastric, breast | HER2-expressing Cancers |
Overview Phase | APPROVED | PHASE_2 | APPROVED | APPROVED | PHASE_1 |
Overview Status | APPROVED | RECRUITING | APPROVED | ACTIVE | ACTIVE |
MoA Mechanism | HER2 internalization → lysosomal MMAE release | — | HER2-mediated internalization → DXd release → DNA damage | HER2-mediated delivery of MMAE | — |
MoA Biomarker | HER2+ | — | HER2 IHC/ISH | HER2 expression | — |
PK/PD Half-life | 4 h | — | ~5.8 days (ADC) | ~5 days | — |
PK/PD Species | Mouse | — | Mouse, Human, Tumor shrinkage, HER2 pathway suppression | Mouse | — |
PK/PD Animal (cat.) | Mouse, In vitro | — | Human, Mouse, In vitro | Mouse, In vitro | — |
PK/PD Experiment | tumor growth inhibition | — | PD | PD | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | Cynomolgus monkey, Mouse, Rat, Hamster, Human | Mouse | — |
Toxicology Animal (cat.) | NHP | — | NHP | Mouse, In vitro | — |
Toxicology Major finding | Thrombocytopenia, hepatotoxicity | Interstitial Lung Disease/Pneumonitis Severe, life-threatening, or fatal interstitial lung diseas | ILD-like lung findings at high exposure | thrombocytopenia, demonstrated for Kadcyla and Enhertu | Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.. Bispecific antibody-drug conjugates (BsADCs) represent a promising strategy to overcome limitations of conventional ADCs in breast cancer, such as tumor heterogeneity and inefficient internalization. This review summarizes recent advances and the therapeutic potential of BsADCs. We conducted a literature review, foc… |
Toxicology CRS | Minimal | — | Minimal | — | — |
Clinical Primary efficacy | ORR 69.3% | ORR 71.7% | ORR 79.7% | ORR 50% | — |
Clinical ORR | 69.3% | 71.7% | 79.7% | ~50% in HER2+ UC | — |
Clinical PFS | — | — | NA | 6.9 mo | — |
Clinical OS | — | — | NA | — | — |
Clinical Result source | ClinicalTrials.gov NCT01120184 | ClinicalTrials.gov NCT04739761 | ClinicalTrials.gov NCT03529110 | RC48-C009 | — |
Clinical Data Tier / Score | A · 90 | C · 74 | S · 100 | B · 89 | C · 3 |
Clinical Program phase | APPROVED | PHASE_2 | APPROVED | APPROVED | PHASE_1 |
Clinical Dose / schedule | q3w | — | q3w | q2w | — |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 5월 22일 (61일 전 · 갱신 권장) | 2026년 7월 18일 (3일 전) | 2026년 7월 18일 (3일 전) | 2026년 5월 22일 (60일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 21일
현재 선택: 5개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1) Roche / Genentech·HER2 ORR 69.3%·t½ 4 h | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki) Daiichi Sankyo / AstraZeneca·HER2 ORR 71.7% | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 ORR 79.7%·t½ ~5.8 days (ADC) | ||
|---|---|---|---|---|---|
Overview Program | Kadcyla (ado-trastuzumab emtansine / T-DM1) | Fam-Trastuzumab Deruxtecan-Nxki | Enhertu (trastuzumab deruxtecan) | Disitamab Vedotin (RC48) | ZW49 |
Overview Company | Roche / Genentech | Daiichi Sankyo / AstraZeneca | Daiichi Sankyo / AstraZeneca | RemeGen | Zymeworks BC Inc. |
Overview Modality | ADC | ADC | ADC | ADC | ANTIBODY |
Overview Target | HER2 | HER2 | HER2 | HER2 | HER2 |
Overview Indication | HER2+ breast cancer | HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer | HER2+ breast cancer, HER2-low, gastric | HER2+ urothelial, gastric, breast | HER2-expressing Cancers |
Overview Phase | APPROVED | PHASE_2 | APPROVED | APPROVED | PHASE_1 |
Overview Status | APPROVED | RECRUITING | APPROVED | ACTIVE | ACTIVE |
MoA Mechanism | HER2 internalization → lysosomal MMAE release | — | HER2-mediated internalization → DXd release → DNA damage | HER2-mediated delivery of MMAE | — |
MoA Biomarker | HER2+ | — | HER2 IHC/ISH | HER2 expression | — |
PK/PD Half-life | 4 h | — | ~5.8 days (ADC) | ~5 days | — |
PK/PD Species | Mouse | — | Mouse, Human, Tumor shrinkage, HER2 pathway suppression | Mouse | — |
PK/PD Animal (cat.) | Mouse, In vitro | — | Human, Mouse, In vitro | Mouse, In vitro | — |
PK/PD Experiment | tumor growth inhibition | — | PD | PD | — |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | — | Cynomolgus monkey, Mouse, Rat, Hamster, Human | Mouse | — |
Toxicology Animal (cat.) | NHP | — | NHP | Mouse, In vitro | — |
Toxicology Major finding | Thrombocytopenia, hepatotoxicity | Interstitial Lung Disease/Pneumonitis Severe, life-threatening, or fatal interstitial lung diseas | ILD-like lung findings at high exposure | thrombocytopenia, demonstrated for Kadcyla and Enhertu | Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.. Bispecific antibody-drug conjugates (BsADCs) represent a promising strategy to overcome limitations of conventional ADCs in breast cancer, such as tumor heterogeneity and inefficient internalization. This review summarizes recent advances and the therapeutic potential of BsADCs. We conducted a literature review, foc… |
Toxicology CRS | Minimal | — | Minimal | — | — |
Clinical Primary efficacy | ORR 69.3% | ORR 71.7% | ORR 79.7% | ORR 50% | — |
Clinical ORR | 69.3% | 71.7% | 79.7% | ~50% in HER2+ UC | — |
Clinical PFS | — | — | NA | 6.9 mo | — |
Clinical OS | — | — | NA | — | — |
Clinical Result source | ClinicalTrials.gov NCT01120184 | ClinicalTrials.gov NCT04739761 | ClinicalTrials.gov NCT03529110 | RC48-C009 | — |
Clinical Data Tier / Score | A · 90 | C · 74 | S · 100 | B · 89 | C · 3 |
Clinical Program phase | APPROVED | PHASE_2 | APPROVED | APPROVED | PHASE_1 |
Clinical Dose / schedule | q3w | — | q3w | q2w | — |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 5월 22일 (61일 전 · 갱신 권장) | 2026년 7월 18일 (3일 전) | 2026년 7월 18일 (3일 전) | 2026년 5월 22일 (60일 전 · 갱신 권장) |
추천 비교
추천 비교